Prognostic and clinicopathological significance of downregulated E-cadherin expression in patients with Non-Small Cell Lung Cancer (NSCLC): A meta-analysis

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Yang, Yan Long ^a   Chen, Ming Wu ^a   Xian, Lei ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

UVOMORULIN; BIOLOGICAL MARKER; CADHERIN;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RACE DIFFERENCE; SAMPLE SIZE; TUMOR DIFFERENTIATION; TUMOR INVASION; CARCINOMA, NON-SMALL-CELL LUNG; EVALUATION STUDY; GENETICS; LUNG NEOPLASMS; META ANALYSIS; METABOLISM; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL;

BIOLOGICAL MARKERS; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; DOWN-REGULATION; HUMANS; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84903640714     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099763     Document Type: Article

References (48)

1. International Agency for Research on Cancer, W.H.O (2012) GLOBOCAN 2012:Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available: http://globocaniarcfr(accessed 2014 Jan 12).
2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, et al. (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24: 4539-4544.
3. Morgensztern D, Ng SH, Gao F, Govindan R (2010) Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 5: 29-33.
4. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, et al. (2009) The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4: 792-801.
5. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, et al. (2012) Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta 1826: 297-311.
6. Birchmeier W, Behrens J (1994) Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198: 11-26.
7. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al. (2003) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://wwwohrica/programs/clinicalepidemiology/ oxfordasp(accessed 2013 Oct 12)
8. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
10. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
11. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
12. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
13. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
14. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, et al. (2000) Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 6: 4789-4796.
15. Kimura K, Endo Y, Yonemura Y, Heizmann CW, Schafer BW, et al. (2000) Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol 16: 1125-1131.
16. Lee YC, Wu CT, Chen CS, Chang YL (2000) E-cadherin expression in surgically-resected non-small cell lung cancers - a clinicopathological study. Thorac Cardiovasc Surg 48: 294-299.
17. Hirata T, Fukuse T, Naiki H, Wada H (2001) Expression of E-cadherin and lymph node metastasis in resected non-small-cell lung cancer. Clin Lung Cancer 3: 134-140.
18. Deeb G, Wang J, Ramnath N, Slocum HK, Wiseman S, et al. (2004) Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. Mod Pathol 17: 430-439.
19. Huang C, Liu D, Masuya D, Nakashima T, Kameyama K, et al. (2005) Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 92: 1231-1239.
20. Tamura M, Ohta Y, Tsunezuka Y, Matsumoto I, Kawakami K, et al. (2005) Prognostic significance of dysadherin expression in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 130: 740-745.
21. Al-Saad S, Al-Shibli K, Donnem T, Persson M, Bremnes RM, et al. (2008) The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer 99: 1476-1483.
22. Cho S, Sung SW, Jheon S, Chung JH (2008) Risk of recurrence in surgically resected stage I adenocarcinoma of the lung: histopathologic and immunohistochemical analysis. Lung 186: 411-419.
23. Zhu ZH, Sun BY, Ma Y, Shao JY, Long H, et al. (2009) Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol 27: 1091-1099.
24. Ono K, Uramoto H, Hanagiri T (2010) Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC. Anticancer Res 30: 3273-3278.
25. Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, et al. (2010) Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer 70: 320-328.
26. Lin Q, Li M, Shen ZY, Xiong LW, Pan XF, et al. (2010) Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small cell lung cancer. Jpn J Clin Oncol 40: 670-676.
27. Sterlacci W, Fiegl M, Hilbe W, Jamnig H, Oberaigner W, et al. (2010) Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. J Thorac Oncol 5: 1325-1336.
28. Ucvet A, Kul C, Gursoy S, Erbaycu AE, Kaya SO, et al. (2011) [Prognostic value of epithelial growth factor receptor, vascular endothelial growth factor, E-cadherin, and p120 catenin in resected non-small cell lung carcinoma]. Arch Bronconeumol 47: 397-402.
29. Yu J, Shi R, Zhang D, Wang E, Qiu X (2011) Expression of integrin-linked kinase in lung squamous cell carcinoma and adenocarcinoma: correlation with E-cadherin expression, tumor microvessel density and clinical outcome. Virchows Arch 458: 99-107.
30. Richardson F, Young GD, Sennello R, Wolf J, Argast GM, et al. (2012) The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second or third-line therapy. Anticancer Res 32: 537-552.
31. Shiwu WU, Lan Y, Wenqing S, Lei Z, Yisheng T (2012) Expression and clinical significance of CD82/KAI1 and E-cadherin in non-small cell lung cancer. Arch Iran Med 15: 707-712.
32. Feng J, Zhang X, Zhu H, Wang X, Ni S, et al. (2012) FoxQ1 overexpression influences poor prognosis in non-small cell lung cancer, associates with the phenomenon of EMT. PLoS One 7: e39937.
33. Kim H, Yoo SB, Sun P, Jin Y, Jheon S, et al. (2013) Alteration of the E-Cadherin/beta-Catenin Complex Is an Independent Poor Prognostic Factor in Lung Adenocarcinoma. Korean J Pathol 47: 44-51.
34. Zhang X, Wang Z, Kang Y, Li X, Ma X, et al. (2014) MCAM expression is associated with poor prognosis in non-small cell lung cancer. Clin Transl Oncol 16: 178-183.
35. Zhang H, Liu J, Yue D, Gao L, Wang D, et al. (2013) Clinical significance of Ecadherin, beta-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma. J Clin Pathol 66: 937-945.
36. Zhao C, Qin Q, Wang QQ, Zhang JR, Xu YL, et al. (2013) SCUBE3 overexpression predicts poor prognosis in non-small cell lung cancer. Biosci Trends 7: 264-269.
37. Lim SC, Jang IG, Kim YC, Park KO (2000) The role of E-cadherin expression in non-small cell lung cancer. J Korean Med Sci 15: 501-506.
38. Pagaki E, Patsouris E, Gonidi M, Athanassiadou AM, Maurikakis M, et al. (2010) The value of E-cadherin/beta-catenin expression in imprints of NCSLC: relationship with clinicopathological factors. Diagn Cytopathol 38: 419-424.
39. Jin S, Zhu W, Shi Q, Zhang Z, Guo R (2012) Clinicopathological significance of lymphatic vessel density marked by D2-40 and E-cadherin expression in non-small-cell lung cancer. Med Oncol 29: 3157-3161.
40. Shi Y, Wu H, Zhang M, Ding L, Meng F, et al. (2013) Expression of the epithelial-mesenchymal transition-related proteins and their clinical significance in lung adenocarcinoma. Diagn Pathol 8: 89.
41. Zhao JQ, Sun FJ, Liu SS, Yang J, Wu YQ, et al. (2013) Expression of connexin 43 and E-cadherin protein and mRNA in non-small cell lung cancers in Chinese patients. Asian Pac J Cancer Prev 14: 639-643.
42. Christofori G (2006) New signals from the invasive front. Nature 441: 444-450.
43. Sahai E, Marshall CJ (2002) RHO-GTPases and cancer. Nat Rev Cancer 2: 133-142.
44. Vincan E, Barker N (2008) The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis 25: 657-663.
45. Ye J, Wu D, Shen J, Wu P, Ni C, et al. (2012) Enrichment of colorectal cancer stem cells through epithelial-mesenchymal transition via CDH1 knockdown. Mol Med Rep 6: 507-512.
46. Arias AM (2001) Epithelial mesenchymal interactions in cancer and development. Cell 105: 425-431.
47. Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4: 118-132.
48. Wu Y, Liu HB, Ding M, Liu JN, Zhan P, et al. (2012) The impact of E-cadherin expression on non-small cell lung cancer survival: a meta-analysis. Mol Biol Rep 39: 9621-9628.